文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

加速大分割全盆腔放疗在高剂量率近距离放疗或立体定向体部放疗前列腺推量前的安全性

Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
PubMed 文献 · Radiat Oncol · 2022-01-20

单中心回顾性分析22例NCCN中高危局限期前列腺癌患者,因 logistical 障碍无法完成五周全盆腔放疗,接受加速大分割全盆腔放疗(41.25 Gy/15次,2.75 Gy/次),后续接受高剂量率近距离放疗(15 Gy/1次)或立体定向体部放疗(19 Gy/2次,9.5 Gy/次)前列腺推量。中位随访32个月,≥2级胃肠和泌尿毒性粗率均为23%,无≥3级毒性,12个月时患者报告泌尿和性功能无差异。结论认为该方案胃肠和泌尿毒性可接受,应进一步验证用于可能存在隐匿淋巴结转移风险者。

要点

  • 加速大分割全盆腔放疗(41.25 Gy/15次)后行高剂量率近距离放疗或立体定向体部放疗推量,≥2级胃肠和泌尿毒性粗率均为23%。
  • 无患者发生≥3级毒性,14%患者出现晚期或持续性2级尿频,5%出现晚期或持续性2级腹泻。
  • 12个月时患者报告泌尿和性功能无差异。

核心结论

  • 加速大分割全盆腔放疗与可接受的胃肠和泌尿毒性相关,应进一步验证用于可能存在隐匿淋巴结转移风险者。

研究设计与样本

  • 单中心回顾性分析,纳入2015年至2017年22例NCCN中高危局限期前列腺癌患者,因无法完成五周全盆腔放疗而接受加速大分割全盆腔放疗(41.25 Gy/15次,2.75 Gy/次),后续接受高剂量率近距离放疗(15 Gy/1次)或立体定向体部放疗(19 Gy/2次,9.5 Gy/次)前列腺推量,雄激素剥夺治疗时长由治疗放疗肿瘤科医生决定,毒性按NCI CTCAE v5.0评估。

主要发现

  • 中位年龄71岁,放疗结束后中位随访32个月(范围2-57)。
  • 临床T1、T2、T3期分别占5%、73%、23%;Gleason评分7分占86%,9分占14%;NCCN中危和高危分别占68%和32%。
  • 91%患者接受高剂量率近距离放疗推量,9%接受立体定向体部放疗推量。
  • ≥2级胃肠和泌尿毒性粗率均为23%;3例(14%)出现晚期或持续性2级尿频,1例(5%)出现晚期或持续性2级腹泻;无患者发生≥3级毒性。
  • 12个月时患者报告泌尿或性功能无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate acute and late genitourinary and gastrointestinal toxicities and patient reported urinary and sexual function following accelerated, hypofractionated external beam radiotherapy to the prostate, seminal vesicles and pelvic lymph nodes and high dose rate (HDR) brachytherapy or stereotactic body radiation therapy (SBRT) prostate boost. METHODS: Patients at a single institution with NCCN intermediate- and high-risk localized prostate cancer with logistical barriers to completing five weeks of whole pelvic radiotherapy (WPRT) were retrospectively reviewed for toxicity following accelerated, hypofractionated WPRT (41.25 Gy in 15 fractions of 2.75 Gy). Patients also received prostate boost radiotherapy with either HDR brachytherapy (1 fraction of 15 Gy) or SBRT (19 Gy in 2 fractions of 9.5 Gy). The duration of androgen deprivation therapy was at the discretion of the treating radiation oncologist. Toxicity was evaluated by NCI CTCAE v 5.0. RESULTS: Between 2015 and 2017, 22 patients with a median age of 71 years completed accelerated, hypofractionated WPRT. Median follow-up from the end of radiotherapy was 32 months (range 2-57). 5%, 73%, and 23% of patients had clinical T1, T2, and T3 disease, respectively. 86% of tumors were Gleason grade 7 and 14% were Gleason grade 9. 68% and 32% of patients had NCCN intermediate- and high-risk disease, respectively. 91% and 9% of patients received HDR brachytherapy and SBRT prostate boost following WPRT, respectively. Crude rates of grade 2 or higher GI and GU toxicities were 23% and 23%, respectively. 3 patients (14%) had late or persistent grade 2 toxicities of urinary frequency and 1 patient (5%) had late or persistent GI toxicity of diarrhea. No patient experienced grade 3 or higher toxicity at any time. No difference in patient-reported urinary or sexual function was noted at 12 months. CONCLUSIONS: Accelerated, hypofractionated whole pelvis radiotherapy was associated with acceptable GU and GI toxicities and should be further validated for those at risk for harboring occult nodal disease.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Phuong C, Chan JW, Ni L, et al. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost. Radiat Oncol. 2022. PMID: 35057827. doi:10.1186/s13014-021-01976-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。